InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,656.00
(
0.09%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
-1.63%
)
Bitcoin
60,957.35
(
-3.32%
)
Post# of 251787
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 185958

Wednesday, 01/14/2015 1:27:33 PM

Wednesday, January 14, 2015 1:27:33 PM

Post# of 251787
India rejects GILD’s Sovaldi patent, but it probably doesn’t matter much insofar as GILD previously licensed Sovaldi to various Indian generic-drug companies for a paltry royalty on sales (#msg-105023468):

http://in.reuters.com/article/2015/01/14/us-gilead-india-patent-idINKBN0KN1ZE20150114

The patent decision shows that India still has a long way to go in protecting foreign companies' drug/biotech IP. This is why I was careful to say that the decision in #msg-109867353 did not constitute a trend.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up